Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that early intervention and treatment with intralesional triamcinolone acetonide may stabilize hairline recession in patients with frontal fibrosing alopecia, although further research is needed for definitive treatment guidelines.

This study found that parents of women with PCOS have a higher prevalence of insulin resistance and Type II diabetes than parents of healthy women.

This commentary discusses the potential use of testosterone therapy for various conditions in women and reports no new clinical results; the authors advocate for more discussion and research in this area.

This review discusses the high prevalence of androgen excess and PCOS in women with type 1 diabetes but reports no new clinical findings; the authors highlight the underdiagnosis of hyperandrogenism in these patients.

This study reports that oral finasteride improved or stabilized hair loss in women with hyperandrogenism but not in postmenopausal women with female pattern hair loss.

This study found that women with polycystic ovary syndrome have higher global adiposity and increased visceral fat, particularly in the ip and mesenteric depots, compared to women without androgen excess.

This study found that metformin treatment significantly improved hair growth in women with PCOS and hirsutism compared to a placebo.

This study describes the enzymatic processes through which DHEA is converted to active sex steroids in human skin, highlighting an androgenic effect on sebaceous glands and estrogenic effects in the vagina.

This study found that spironolactone was significantly more effective than finasteride in reducing hirsutism scores over 9 months, despite more side effects occurring in the spironolactone group.

This report discusses cases of frontal fibrosing alopecia developing after hair transplantation for androgenetic alopecia, without presenting new clinical findings.

This review examines the evaluation and management of hirsutism and hyperandrogenism in postmenopausal women and reports no new clinical findings.

Randomized trials reported that testosterone therapy improved sexual function in postmenopausal women with hypoactive sexual desire disorder, particularly those who had undergone oophorectomy, with reversible and well-tolerated side effects.

In this study, women with PCOS had a higher prevalence of hepatic steatosis compared to controls, with associated metabolic issues like insulin resistance and metabolic syndrome.

This study found that 5 mg/day oral finasteride was effective and safe for improving hair outcomes in normoandrogenic postmenopausal women with androgenetic alopecia over 18 months.

This study suggests that women with polycystic ovary syndrome may have a distinct metabolomic profile, differing in levels of amino acids, organic acids, and lipids compared to controls.

This review discusses diagnostic and treatment considerations for women with cutaneous hyperandrogenism, noting therapeutic options are more effective for hirsutism and acne than for androgenetic alopecia, but reports no new clinical results.

This study observed that frontal fibrosing alopecia also occurs in men, with clinical features and areas of involvement similar to those seen in women, but often affecting sideburns and facial hair.

This review discusses the challenges of using surrogate variables versus primary clinical end-points in PCOS trials and reports no new research results; the authors suggest focusing future studies on primary outcomes.

In this study, changes in hair cycle phases during pregnancy and the post-partum period showed a rise in telogen rates after delivery, especially among non-breastfeeding women, but no drastic exaggerations were noted.

This study found that women with polycystic ovary syndrome phenotypes A and B had the highest prevalence of metabolic syndrome, and that the visceral adiposity index may help predict metabolic risk.

This article reviews androgen excess and cardiometabolic risks in women, highlighting increased cardiovascular disease risk in those with polycystic ovary syndrome, but reports no new clinical results.

This study concluded that heterozygosity for CYP21 mutations is associated with higher mean and free testosterone levels in women but does not significantly increase their risk of developing clinically evident hyperandrogenism.

This study identified trilauric glyceride and decanoylcarnitine as potential biomarkers for diagnosing PCOS in patients with and without insulin resistance, suggesting significant metabolic alterations in these conditions.

This review examines the debated link between iron deficiency and nonscarring scalp alopecia in women, offering no new clinical results but emphasizing the need for further research and well-designed trials.

This review summarizes the influence of gene polymorphisms on genetic predisposition to polycystic ovary syndrome, but reports no new experimental or clinical results.

This study found that an intermittent low-dose regimen of finasteride (2.5 mg every 3 days) effectively reduced hirsutism scores in women with idiopathic hirsutism or polycystic ovary syndrome, with fewer side effects than continuous daily administration.

This study suggests that young women with low prolactin levels may face higher cardiometabolic risk, and reducing cabergoline dosage reversed related metabolic disturbances.

This review discusses the impact, pathophysiology, and health risks of obesity and the metabolic syndrome in polycystic ovarian syndrome, emphasizing the potential life-saving benefits of recognition and treatment, but it reports no new results.

This review discusses the role of sex hormones in cardiac hypertrophy and notes that estrogen provides protection against hypertrophy in pre-menopausal women, which is reduced after menopause but partially restored with estrogen therapy.

This study found that in women with polycystic ovary syndrome, xanthine oxidase activity is a useful marker for oxidative stress and is positively correlated with inflammatory markers and cardiovascular disease risk factors.